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Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a very rare form of skin lymphoma that is localized primarily to
the subcutaneous adipose tissue without palpable involvement of the lymph nodes. Diagnosis of SPTCL is a challenge, especially
during its early phases when symptoms mimic other, more common conditions, such as benign panniculitis, eczema, dermatitis,
psoriasis and cellulitis. Clinical and systemic features are nonspeciﬁc and can include fever, chills, and weight loss. Further
complicating diagnosis is the high number of false negatives provided by biopsy. Here we present a case of SPTCL that illustrates
thefull courseofthedisease,frompresentationandmultiplemisdiagnosesto correct diseaserecognitionandsuccessfultreatment.
A review of the challenges of diagnosis is provided with recommendations for more accurate and timely recognition of SPTCL.
1.Introduction
Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is
a very rare form of skin lymphoma that is localized primarily
to the subcutaneousadipose tissue without palpable involve-
ment of the lymph nodes. It was ﬁrst described in 1991 in
an 8-case series [1] but was not recognized as a distinct
entity by the World Health Organization until 2001 [2]. It
is estimated that SPTCL accountsforless than 1% of all non-
Hodgkins lymphomas [2]. Most often it presents as multiple,
painless, subcutaneous nodules on the extremities and
trunk. In its early phases, the nodules may resolve without
treatment and subsequently new nodules may develop on
the same or diﬀerent skin locations. Diagnosis of SPTCL is
a challenge, especially during initial contact with physicians
when symptoms mimic other, more common conditions,
such as benign panniculitis, eczema, dermatitis, psoriasis,
cellulites, and other skin and soft tissue infections. Clinical
and systemic symptoms are nonspeciﬁc and can include
fever, chills, and weight loss; approximately half of patients
develop mild cytopenias. More serious conditions associated
with SPTCL include hepatosplenomegaly, mucosal ulcers,
serosal eﬀusions, hemophagocytosis syndrome (HPS), and
pancytopenia, though these are less common [3, 4].
Here we describe a case of a middle-aged woman who
presented with recurring fevers of unknown origin and an
8-month history of thigh and leg swelling and rash. After
several in-patient and out-patient visits, she was diagnosed
with SPTCL based on clinical history and results of surgical
pathology. Challenges of diagnosis are discussed.
2.Case Report
2.1. First Admission. A 44-year-old morbidly obese female
presented to the emergency department with fever of
unknown origin (101.8◦F at admission) and chills for 10
days that were unresponsive to antibiotics (cephalexin).
She had a history of bulimia, depression, anemia, gastritis,
hypertension, and rheumatic fever. She also had chronic
skin lesions on the left lower lateral thigh and left upper
calf for eight months but reported increased pain in those
areas with development of yellow discharge, light bleeding,2 Journal of Skin Cancer
and numbness over the past 10 days. The rash showed
multipleareasofactivity and remission presenting as spread-
ing rings (Figure 1). Numerous visits to dermatologists,
plastic surgeons, and infectious disease specialists resulted in
multiple failed courses of oral antibiotics. Several skin lesion
biopsies resulted in diﬀerential diagnoses of lichen sim-
plex chronicus versus panniculitis versus prurigo nodularis.
A deep fascia biopsy one month prior was interpreted as
granulomatous panniculitis with negative stains for acid-fast
bacilli and fungi.
At admission, labs were within normal limits with the
exception of low WBC (3.2K/uL, Normal = 4.8–10.8K/uL)
and abnormal liver function tests (LFT) (BUN = 6mg/dL,
N = 7–17mg/dL; ALT = 79U/L, N = 9–52U/L; AST =
85U/L, N = 14–36U/L; AlkPhos = 164U/L, N =
37–126U/L). Vancomycin and Zosyn were started. Wound
culture was positive for Streptococcus agalactiae. Deep tissue
biopsy was performed. HIV and Lyme tests were negative.
There was progressive worsening of neutropenia (WBC =
2.4K/uL)andLFT(BUN= 4mg/dL;AL T= 116U/L;AST =
146U/L; AlkPhos = 212U/L). Hepatitis B and C tests were
negative. Fever improved with antibiotics and patient was
discharged home on oral levoﬂoxacin.
Results of biopsy of left upper thigh showed inter-
face/lichenoid dermatitis with granulomatous features and
lobular fat necrosis. Left lower leg biopsy showed similar, but
more subtle, results. At this time, the pathologist diﬀerential
diagnoses included collagen vascular disease (e.g., lupus
erythematosus), foreign body reaction/unusual drug erup-
tion, sarcoidosis, and Kikuchi’s disease. Culture from biopsy
grew Pantoea Agglomerans. Due to clinical presentation and
positive culture results, infectious etiology was suspected.
A four-week course of ciproﬂoxacin was prescribed.
2.2. First Admission. Three months later, the patient was
readmitted with periodic high fever, chills, nausea, night
sweats, and vomiting. She continued to be neutropenic
(WBC = 2.9) with slightly elevated LFT (ALT = 57U/L;
AST = 57U/L; AlkPhos = 149U/L). Lesions were grossly
unresponsive to previous antibiotics. Wound cultures and
cancerantigen125werenormal. Afterexcisionalbiopsyfrom
the left lower leg and the left groin area, including a lymph
node, she was discharged home on antibiotics. The biopsy
samples were submitted to an outside lab for review.
Surgical pathology for the left lower leg was consistent
with mild perivascular small lymphocytic inﬁltrate without
speciﬁcity. On low-power ﬁeld, results for the left groin area
sample showed extranodal ﬁbroadipose tissue containing
a lymphoid inﬁltrate with a pattern similar to lobular and
septal panniculitis (at 10x magniﬁcation) (Figure 2(a)). On
high-power ﬁeld (Figures 2(b)–2(g)), the lymphoid cells
were markedly atypical with irregular nuclei. There were
numerous fat cells rimmed by atypical lymphoid cells as well
as abundant single-cell necrosis. There were scattered and
dispersed histiocytes, some with phagocytic cell debris. The
septae had areas of necrosis and ﬁbrinoid deposition. The
lymph node biopsy revealed a spectrum of small, medium,
andsomelargecells.TheseresultsareconsistentwithSPTCL.
Immunohistochemical stains for the left groin area
sample were positive for CD3 and CD8 but negative for
CD4 and CD56 (Figure 2). CD4 was positive in scattered
small lymphocytes and frequent interspersed histiocytes.
CD20 was positive in rare, scattered B-cells. The lymph node
had preserved architecture, reactive germinal centers, and
paracortical hyperplasia with a spectrum of small, medium,
and some large cells; there was no deﬁnite involvement by
lymphoma. Based on surgical pathology results, a diagnosis
of SPTCL involving extranodal adipose tissue in the soft
tissue of left groin area was made. The surgical pathology
results were most consistent with an SPTCL phenotype
referred to as TCRαβ. The patient was referred to oncology
and began CHOP (i.e., Cyclophosphamide, Adriamycin,
Vincristine, and Prednisone) therapy regimen.
2.3. First Admission. Patient was admitted 5 months later
for complicated skin and skin structure infection (CSSSI) of
the lower abdomen and mons pubis, right groin, and upper
thigh, due to culture-proven MRSA. The areas that had
previously showed signs of SPTCL were responding very
favorably to CHOP therapy (Figure 3). CSSSI was success-
fully treated with 4 weeks of IV daptomycin and rifampin.
Patient continuestofollow upwith the oncologistforfurther
treatment, as necessary.
3.Discussion
There are two distinct types of SPTCL, classiﬁed by the
T-cell receptor (TCR) phenotype and immunophenotypic
characteristics. The ﬁrst, TCRαβ, is characterized by an
indolent, protracted course and is usually CD4−,C D 8 +,a n d
CD56−.T h es e c o n d ,T C R γδ, is associated with rapid clinical
deterioration and coexisting hemophagocytosis syndrome
(HPS); it is usually CD4−,C D 8 −,a n dC D 5 6 + [5]. Currently,
the medical community uses the SPTCL designation for
patients with TCRαβ,w h e r e a sT C R γδ is designated as cuta-
neous gamma/delta positive T-cell lymphoma (Cγδ-TCR)
[4, 6]. For the purposes of the current report, SPTCL is
being used to denote the umbrella of patients with TCRγδ
or Cγδ-TCR, while the individual phenotypes are being used
to describe the speciﬁc phenotypes.
Diagnosis of SPTCL is based on pathological exam-
ination of skin and subcutaneous tissue, immunohisto-
chemical staining patterns, molecular analysis, and clinical
characteristics. Patients with SPTCL present with nodules
or plaques; ulcerations may also develop, but this occurs in
a signiﬁcantly larger proportion of patients with the Cγδ-
TCLphenotype(45%versus6%inTCRαβ)[4].B-symptoms
(e.g., fever, night sweats, and weight loss) and cytopenias
are common in both phenotypes. Approximately 75% of
patientswithSPTCLhavemultifocalcutaneousinvolvement.
Lesions typically developon the arms, legs, and/or trunk [4].
Previous to diagnosis of SPTCL, the patient we report on
had numerous visits to both in-patient units and out-patient
clinics where benign panniculitis was the primary diagnosis,
ac o m m o no c c u r r e n c ei nc a s e so fS P T C L .
As described and illustrated by Parveen and Thompson
[6] and Paulli and colleagues [7], SPTCL is characterizedJournal of Skin Cancer 3
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Figure 1: Cutaneous lesions on the thigh, which had been present for 8 months with recent worsening in severity.
(a) (b) (c)
(d) (e) (f) (g)
Figure 2: Biopsy of soft tissue from the left thigh revealed: (a) at 10x magniﬁcation shows lymphoid inﬁltrate with pattern resembling
lobular and septal panniculitis, and (b) at 40x magniﬁcation shows lymphoid inﬁltrate with abundant cytoplasm. At 100x magniﬁcation
with oil-immersionbiopsy showed (c) atypical lymphoid cells with atypical and irregular nuclei as well as numerous fat cells, (d) numerous
single-cell necroses andatypical lymphoidinﬁltrate, (e) mitotic ﬁgure in the center with areas ofnecrosis and ﬁbrosis,(f) mitoticﬁgure with
scattered histiocytes and area of necrosis, and (g) area of necrotic debris.
histologicallybyneoplasticlymphoidcellsinﬁltrating mainly
the lobular areas of the subcutaneous tissue. In cases of
Cγδ-TCL, involvement of the epidermal/dermal tissue may
also exist. Lymphocytes exhibit slight atypical features,
including hyperchromatic, angulated nuclei, and indistinct
cell borders. Admixed benign histiocytes, plasma cells, and
neutrophils are present, mimicking benign panniculitis [8].
Scattered mitoses, apoptotic cells, karyorrhectic debris, focal
areas of fat necrosis, and rimming of individual fat cells by
neoplastic cells are also common in SPTCL [9–11].
Histologically, SPTCL can be misinterpreted as other,
more common diseases and conditions. Rimming of fat cells
can beseen in primary and secondary cutaneouslymphomas
and in lobular panniculitis [12]. Some cases of SPTCL
have features of vague granuloma formation, which is also
present in granulomatous panniculitis. Vasculitis has been
rarely reported; angiocentricity and angiodestruction are
not features of SPTCL. As in our case, multiple, sequential
biopsies may be needed for accurate diagnosis. Use of high
power ﬁelds is recommended.4 Journal of Skin Cancer
Figure 3: Cutaneous lesions after treatment with ﬁve cycles of
CHOP chemotherapy (Five months after second admission).
Immunophenotyping is very helpful for diagnosing
SPTCL. The neoplastic cells in SPTCL are cytotoxic T cells
that are CD3+ and CD4−.T C R αβ cells are CD8+ and usually
CD30− and CD56− whereas Cγδ-TCL is usually CD8−,
CD56+,a n dC D 3 0 + [3, 4, 13]. In terms of diﬀerential diag-
nosis, benign panniculitis usually has aggregates of CD20−
B-cells mixed with CD3− cells that are both CD4− and
CD8− [4]. Lupus erythematosus panniculitis is commonly
CD4+ without CD8+ T cells [14]. Primary cutaneous CD56+
natural killer-like T-cell lymphoma is both CD30+ and
CD56+, and unlike SPTCL, is often positive for Epstein-Barr
[15]. In our case, the left groin tissue sample exhibited classic
immunophenotyping characteristics of TCRαβ, including
abnormal lymphoid cells from extranodal tissues that were
CD3+,C D 4 −,C D 8 +,a n dC D 5 6 −. Additionally, scattered B-
cells were CD20+. Taken together, these ﬁndings rule-out
most diﬀerential diagnoses.
One diﬀerential diagnosis that is of particular interest
is Pfeifer-Weber-Christian Disease (PWCD), which is a rare
inﬂammatory disorder of the subcutaneous adipose tissue.
PWCD is characterized by recurrent subcutaneous inﬂam-
matory nodules paired with systemic symptoms, such as
fever and malaise. It has been theorized that it is a T-cell
mediated autoinﬂammatory condition [16]. Since PWCD
is a diagnosis based on exclusion, and since it can present
very similar to SPTCL, it is generally thought that some, if
not many, described cases of PWCD may indeed be SPTCL.
Furthermore, since cyclosporine is an often-successful form
of treatment for PWCD and for TCRαβ, misidentiﬁcation of
the disease becomes more of a possibility.
Imaging technology has begun to be utilized in the
diagnostic process; it is also being used for monitoring
disease response to therapy. Positron emission tomography
(PET) scanning may be useful for staging SPTCL and
also for monitoring treatment responses while a patient is
undergoing chemotherapy [16]. Whole body MRI is also
appropriatefor assessing the extent of disease and examining
response to treatment [17].
As described by Go and Wester [18], lesions due to
TCRαβ initially respond well to treatment with steroids, but
more than 70% of responders achieve only short remission
periods. Further research regarding the use of ciclosporins
for treatment of SPTCL is ongoing [19]. Exclusive treatment
with radiotherapy in cases of localized skin lesions is highly
eﬀective, with reported partial or full response rates of
around 80%. CHOP-like therapies are the most commonly
used initial types of chemotherapy, with overall complete
or partial remission rates of 50%. Few cases have reported
use of intensive chemotherapy (e.g., ProMACE-CytaBOM,
MACOP-B) or ﬂudarabine-based chemotherapies as initial
treatments, although these have been relatively eﬀective
with overall remission rates of more than 70%. Numerous
types of salvage therapies have been used, though rarely,
including ALL, Mini-BEAM, and ESHAP. When imple-
mented, remission rates are lower than for CHOP-like
chemotherapy. High dose chemotherapy is the most eﬀective
treatment with more than 90% remission, but is very rarely
used. In some cases, autologous bone marrow transplants
and stem cell transplants have been implemented. Biologic
agents, such as interferon-α, have been used for a limited
number of cases without strong evidence of eﬀectiveness
[18].
Treatment of aggressive cases of SPTCL with anthra-
cycline-containing chemotherapy has generally had poor
outcomes. There has been one report of successful use
of purine analog ﬂudarabine in combination with mitox-
antrone and dexamethasone (FND) for treating a multifocal
and aggressive CD8+ SPTCL [20]; the patient achieved com-
pleteremissionafteronecourseoftreatment and,afteratotal
of six courses, remained in remission for more than 3 years.
Additionally, a case of SPTCL with HPS that was resistant to
CHOP therapy was reported to achieve complete remission
(with 3-year followup) after combination chemotherapy
using the BFM-90 protocol [21]. SPTCL in our patient was
highly responsive to CHOP therapy.
The overall ﬁve-year survival rate for TCRαβ exceeds
80%. The presence of HPS, however, signiﬁcantly decreases
survival rates; the ﬁve-year survival rates for TCRαβ without
HPS are around 90%, whereas if HPS is present the rate falls
to less than 50%. On the other hand, there is rapid clinical
deterioration in Cγδ-TCL whether HPS is present or not,
with a 5-year survival rate of less than 20% in either group
[3, 4]. Even without treatment, metastasis of TCRαβ SPTCL
i sv e r yr a r e .M e t a s t a s i si sm o r ec o m m o ni nC γδ-TCL, and
metastatic sites have included the lungs, liver, kidneys, CNS,
and oral mucosa.
SPTCL is a rare disease that can be a challenge to
diagnose. When a patient presents with a long history
of panniculitis-like lesions that have been unresponsive to
topical and antibiotic therapy and are accompanied by
nonspeciﬁc clinical symptoms, SPTCL should be considered.
Neutropenia that does not respond to antibiotics is another
clue for diagnosis. Biopsy with a sample deep enough to
include subcutaneous tissue is essential; additionally, high
power ﬁelds to analyze samples should be used in order to
make an accurate diﬀerential diagnosis. Immunochemistry
should be completed since it is the best way to diﬀerentiate
between SPTCL and other, more common diagnoses, as well
astoguidetreatmentdecisions.Delayeddiagnosiscanleadto
worsening ofsymptoms and higher probability ofmorbidity,
such as severe skin infections.Journal of Skin Cancer 5
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